Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Jennifer Bordeaux"'
Autor:
Xun Li, Jennifer Bordeaux, Jaspreet Kaur, Sarah Choi, Lisa Adams, Jimmie Lim, Sophia Kekchidou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0ffd958d3a534f68b9a2cf779aa67be9
Autor:
Sarah Johnson, Xun Li, Jennifer Bordeaux, Shabnam Tangri, Naveen Dakappagari, Nathan Riccitelli, Nancy Valencia, Ju Young Kim, Nathan Roscoe, James Santos, Justin Santos, Jacob Levy, Deepika Asnani, Tracie Cobb, Angela McIntosh, Reinhold Pollner
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/b1a52b567f874f498552ae4f0e51ec45
Autor:
Peter J. Siska, Romany A. N. Johnpulle, Alice Zhou, Jennifer Bordeaux, Ju Young Kim, Bashar Dabbas, Naveen Dakappagari, Jeffrey C. Rathmell, W. Kimryn Rathmell, Alicia K. Morgans, Justin M. Balko, Douglas B. Johnson
Publikováno v:
OncoImmunology, Vol 6, Iss 4 (2017)
Platinum-based chemotherapy is usually curative for patients with testicular germ cell tumors (TGCT), but a subset of patients experience disease progression and poor clinical outcomes. Here, we tested whether immune profiling of TGCT could identify
Externí odkaz:
https://doaj.org/article/cf5517a5903449779442327d697d03c0
Autor:
Jennifer Bordeaux, Allison W. Welsh, Seema Agarwal, Elizabeth Killiam, Maria T. Baquero, Jason A. Hanna, Valsamo K. Anagnostou, David L. Rimm
Publikováno v:
BioTechniques, Vol 48, Iss 3, Pp 197-209 (2010)
Antibodies are among the most frequently used tools in basic science research and in clinical assays, but there are no universally accepted guidelines or standardized methods for determining the validity of these reagents. Furthermore, for commercial
Externí odkaz:
https://doaj.org/article/fe18292d1f2a4b0e90869b79af89aa60
Autor:
Maria Vassilakopoulou, Taiwo Togun, Urania Dafni, Huan Cheng, Jennifer Bordeaux, Veronique M Neumeister, Mattheos Bobos, George Pentheroudakis, Dimosthenis V Skarlos, Dimitrios Pectasides, Vassiliki Kotoula, George Fountzilas, David L Rimm, Amanda Psyrri
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e99131 (2014)
We sought to determine the predictive value of in situ mRNA measurement compared to traditional methods on a cohort of trastuzumab-treated metastatic breast cancer patients.A tissue microarray composed of 149, classified as HER2-positive, metastatic
Externí odkaz:
https://doaj.org/article/39507788764544b193acd5dff1a36f26
Autor:
Yalai Bai, Huan Cheng, Jennifer Bordeaux, Veronique Neumeister, Sudha Kumar, David L Rimm, David F Stern
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e79901 (2013)
HER2/Neu (ErbB-2) overexpression, which occurs in 15-20% of breast cancer cases, is associated with better response to treatment with the drug trastuzumab. PhosphoHER2 (pHER2) has been evaluated for prediction of response to trastuzumab. Both markers
Externí odkaz:
https://doaj.org/article/120a4aeb316c45a5a4f081c211f4e8c9
Autor:
Ahmad A. Tarhini, John M. Kirkwood, Hassane M. Zarour, Amy Rose, Cindy Sander, Matthew P. Holtzman, James F. Pingpank, Christian Laing, Zeni Alfonso, Jennifer Tsau, Anil Pahuja, Ghanashyam Sarikonda, Beiru Chen, Ju Young Kim, Jehovana O. Bender, IlaSri B. Summit, Jennifer Bordeaux, Joseph J. Skitzki, Igor Puzanov, Marc S. Ernstoff, Lisa H. Butterfield, Rogerio I. Neves, Joseph J. Drabick, Arivarasan Karunamurthy, Diwakar Davar, Yan Zang, Yan Lin, Huang Lin, Dustin McCurry, Yana G. Najjar
Treatment significantly affects the circulating immune compartment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eeb4ff31ce1f39f892e656546912333
https://doi.org/10.1158/1078-0432.22481585
https://doi.org/10.1158/1078-0432.22481585
Autor:
Ahmad A. Tarhini, John M. Kirkwood, Hassane M. Zarour, Amy Rose, Cindy Sander, Matthew P. Holtzman, James F. Pingpank, Christian Laing, Zeni Alfonso, Jennifer Tsau, Anil Pahuja, Ghanashyam Sarikonda, Beiru Chen, Ju Young Kim, Jehovana O. Bender, IlaSri B. Summit, Jennifer Bordeaux, Joseph J. Skitzki, Igor Puzanov, Marc S. Ernstoff, Lisa H. Butterfield, Rogerio I. Neves, Joseph J. Drabick, Arivarasan Karunamurthy, Diwakar Davar, Yan Zang, Yan Lin, Huang Lin, Dustin McCurry, Yana G. Najjar
Representative gating strategy illustrating (A) CD4 and CD8 T cell identification (B) expression of ICOS on CD4 positive T cells (C) expression of PD-1 and Ki-67 within PD-1 positive cells and (D) expression of CD38/HLA-DR, PD-1 and KI-67 within CD8+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05be2d07b58f4dfd685805c3833c030c
https://doi.org/10.1158/1078-0432.22481579.v1
https://doi.org/10.1158/1078-0432.22481579.v1
Autor:
Ahmad A. Tarhini, John M. Kirkwood, Hassane M. Zarour, Amy Rose, Cindy Sander, Matthew P. Holtzman, James F. Pingpank, Christian Laing, Zeni Alfonso, Jennifer Tsau, Anil Pahuja, Ghanashyam Sarikonda, Beiru Chen, Ju Young Kim, Jehovana O. Bender, IlaSri B. Summit, Jennifer Bordeaux, Joseph J. Skitzki, Igor Puzanov, Marc S. Ernstoff, Lisa H. Butterfield, Rogerio I. Neves, Joseph J. Drabick, Arivarasan Karunamurthy, Diwakar Davar, Yan Zang, Yan Lin, Huang Lin, Dustin McCurry, Yana G. Najjar
Treatment significantly affects the circulating immune compartment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf8661283efc187904b5f5fcda67641
https://doi.org/10.1158/1078-0432.22481576.v1
https://doi.org/10.1158/1078-0432.22481576.v1
Data from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Autor:
Ahmad A. Tarhini, John M. Kirkwood, Hassane M. Zarour, Amy Rose, Cindy Sander, Matthew P. Holtzman, James F. Pingpank, Christian Laing, Zeni Alfonso, Jennifer Tsau, Anil Pahuja, Ghanashyam Sarikonda, Beiru Chen, Ju Young Kim, Jehovana O. Bender, IlaSri B. Summit, Jennifer Bordeaux, Joseph J. Skitzki, Igor Puzanov, Marc S. Ernstoff, Lisa H. Butterfield, Rogerio I. Neves, Joseph J. Drabick, Arivarasan Karunamurthy, Diwakar Davar, Yan Zang, Yan Lin, Huang Lin, Dustin McCurry, Yana G. Najjar
Purpose:Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1471b78d10ef705c6b751e83f0d0d685
https://doi.org/10.1158/1078-0432.c.6530735.v1
https://doi.org/10.1158/1078-0432.c.6530735.v1